Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials

American Journal of Cardiology

Volumn 104, Issue 10 SUPPL., 2009, Pages 3E-9E

  Deedwania, Prakash ^a,b   Singh, Vibhuti ^c,d   Davidson, Michael H ^e,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Suncoast Cardiovascular Center   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 71749098582     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.09.013     Document Type: Article

References (42)

1. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106 (2002) 3143-3421
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
3. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
4. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C., and for the European Consensus Panel on H.D.L.-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk, the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
5. Sacks F.M., and Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
6. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27 suppl 1 (2004) S68-S71
7. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
8. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62 (1977) 707-714
9. Stampfer M.J., Sacks F.M., Salvin S., Willett W.C., and Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325 (1991) 373-381
10. Goldbourt U., Yaari J.S., and Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8,000 men. Arterioscler Thromb Vasc Biol 17 (1997) 107-113
11. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
12. Lewis G.F., and Rader J.D. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
13. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
14. Barter P.J. Cardioprotective effects of high-density lipoproteins: the evidence strengthens. Arterioscler Thromb Vasc Biol 25 (2005) 1305-1306
15. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006) 1352-1364
16. Sposito A.C., and Chapman M.J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 22 (2002) 1524-1534
17. Gotto Jr. A.M., Boccuzzi S.J., Cook J.R., Alexander C.M., Roehm J.B., Meyer G.S., Clearfield M., Weis S., Whitney E., and AFCAPS/TexCAPS Research Group. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 86 (2000) 1176-1181
18. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., and Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
19. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
20. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
21. Chapman M.J. Are the effects of statins on HDL-cholesterol clinically relevant?. Eur Heart J 6 suppl C (2004) C58-C63
22. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto Jr. A.M., and AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
23. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 256 (1986) 2835-2838
24. Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
25. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
26. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248 (1982) 1465-1477
27. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 suppl (1996) S11-S20
28. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R., and Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
29. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
30. Deedwania P., Stone P.H., Bairey Merz C.N., Cosin-Aguilar J., Koylan N., Luo D., Ouyang P., Piotrowicz R., Schenck-Gustafsson K., Sellier P., et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease. Circulation 115 (2007) 700-707
31. Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M.f.t.P.o.A.E.T.i.M.I.22 I. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
32. LaRosa J.C., He J., and Vuppiuturi S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
33. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., Kastelein J.J., LaRosa J.C., Schachner H., Shepherd J., Waters D.D., and Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
35. Amarenco P., Labreuche J., and Touboul P.J. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196 (2008) 489-496
36. Windler E., Schoffauer M., and Zyriax B.C. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab Vasc Dis Res 4 (2007) 136-142
37. Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
38. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.-C., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J., and Wenger N.K.f.t.T.t.N.T.(T.N.T.) I. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
39. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
40. Bezafibrate Infarction Prevention. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
41. Ridker P.M., Buring J.E., and Shih J. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
42. Karthikeyan G., Teo K.K., Islam S., McQueen M.J., Pais P., Wang X., Sato H., Lang C.C., Sitthi-Amorn C., Pandey M.R., et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol 53 (2009) 244-253